Cargando…

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse

Among vaccines aimed at treating substance use disorders, those targeting opioids present several unique medication development challenges. 1) Opioid overdose is a common complication of abuse, so it is desirable for an opioid vaccine to block the toxic as well as the addictive effects of opioids. 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Raleigh, M. D., Peterson, S. J., Laudenbach, M., Baruffaldi, F., Carroll, F. I., Comer, S. D., Navarro, H. A., Langston, T. L., Runyon, S. P., Winston, S., Pravetoni, M., Pentel, P. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711015/
https://www.ncbi.nlm.nih.gov/pubmed/29194445
http://dx.doi.org/10.1371/journal.pone.0184876
_version_ 1783282989215514624
author Raleigh, M. D.
Peterson, S. J.
Laudenbach, M.
Baruffaldi, F.
Carroll, F. I.
Comer, S. D.
Navarro, H. A.
Langston, T. L.
Runyon, S. P.
Winston, S.
Pravetoni, M.
Pentel, P. R.
author_facet Raleigh, M. D.
Peterson, S. J.
Laudenbach, M.
Baruffaldi, F.
Carroll, F. I.
Comer, S. D.
Navarro, H. A.
Langston, T. L.
Runyon, S. P.
Winston, S.
Pravetoni, M.
Pentel, P. R.
author_sort Raleigh, M. D.
collection PubMed
description Among vaccines aimed at treating substance use disorders, those targeting opioids present several unique medication development challenges. 1) Opioid overdose is a common complication of abuse, so it is desirable for an opioid vaccine to block the toxic as well as the addictive effects of opioids. 2) It is important that an opioid vaccine not interfere with the action of opioid antagonists used to reverse opioid overdose or treat addiction. 3) Some opioids are immunosuppressive and chronic ongoing opioid use could interfere with vaccine immunogenicity. 4) Although antibody-bound oxycodone is unable to enter the brain because of its size, it might still be able to activate peripheral opioid receptors. To assess vaccine impact on opioid toxicity, rats vaccinated with oxycodone conjugated to keyhole limpet hemocyanin subunit dimer (OXY-dKLH) adsorbed to alum or controls vaccinated with dKLH were compared with regard to oxycodone-induced hotplate analgesia and oxycodone-induced respiratory depression and bradycardia. Vaccination shifted the dose-response curves to the right, representing protection, for each of these endpoints. Naloxone was equally effective in both OXY-dKLH and control groups, providing complete and rapid reversal of respiratory depression. The administration of a long-acting naltrexone formulation during vaccination did not impair vaccine immunogenicity in mice. Similarly, serum anti-oxycodone antibody titers were not altered by continuous morphine infusion during vaccination compared to opioid-naïve controls. Competitive ELISA assay showed negligible or low affinity of immune antiserum for endogenous opioids or opioid antagonists. In vitro receptor binding assays showed that antibody-bound oxycodone does not activate mu opioid receptors. These data support further study of OXY-dKLH as a potential treatment for oxycodone abuse and suggest that vaccination might also reduce the severity of oxycodone overdose.
format Online
Article
Text
id pubmed-5711015
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57110152017-12-15 Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse Raleigh, M. D. Peterson, S. J. Laudenbach, M. Baruffaldi, F. Carroll, F. I. Comer, S. D. Navarro, H. A. Langston, T. L. Runyon, S. P. Winston, S. Pravetoni, M. Pentel, P. R. PLoS One Research Article Among vaccines aimed at treating substance use disorders, those targeting opioids present several unique medication development challenges. 1) Opioid overdose is a common complication of abuse, so it is desirable for an opioid vaccine to block the toxic as well as the addictive effects of opioids. 2) It is important that an opioid vaccine not interfere with the action of opioid antagonists used to reverse opioid overdose or treat addiction. 3) Some opioids are immunosuppressive and chronic ongoing opioid use could interfere with vaccine immunogenicity. 4) Although antibody-bound oxycodone is unable to enter the brain because of its size, it might still be able to activate peripheral opioid receptors. To assess vaccine impact on opioid toxicity, rats vaccinated with oxycodone conjugated to keyhole limpet hemocyanin subunit dimer (OXY-dKLH) adsorbed to alum or controls vaccinated with dKLH were compared with regard to oxycodone-induced hotplate analgesia and oxycodone-induced respiratory depression and bradycardia. Vaccination shifted the dose-response curves to the right, representing protection, for each of these endpoints. Naloxone was equally effective in both OXY-dKLH and control groups, providing complete and rapid reversal of respiratory depression. The administration of a long-acting naltrexone formulation during vaccination did not impair vaccine immunogenicity in mice. Similarly, serum anti-oxycodone antibody titers were not altered by continuous morphine infusion during vaccination compared to opioid-naïve controls. Competitive ELISA assay showed negligible or low affinity of immune antiserum for endogenous opioids or opioid antagonists. In vitro receptor binding assays showed that antibody-bound oxycodone does not activate mu opioid receptors. These data support further study of OXY-dKLH as a potential treatment for oxycodone abuse and suggest that vaccination might also reduce the severity of oxycodone overdose. Public Library of Science 2017-12-01 /pmc/articles/PMC5711015/ /pubmed/29194445 http://dx.doi.org/10.1371/journal.pone.0184876 Text en © 2017 Raleigh et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Raleigh, M. D.
Peterson, S. J.
Laudenbach, M.
Baruffaldi, F.
Carroll, F. I.
Comer, S. D.
Navarro, H. A.
Langston, T. L.
Runyon, S. P.
Winston, S.
Pravetoni, M.
Pentel, P. R.
Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
title Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
title_full Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
title_fullStr Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
title_full_unstemmed Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
title_short Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
title_sort safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711015/
https://www.ncbi.nlm.nih.gov/pubmed/29194445
http://dx.doi.org/10.1371/journal.pone.0184876
work_keys_str_mv AT raleighmd safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT petersonsj safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT laudenbachm safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT baruffaldif safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT carrollfi safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT comersd safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT navarroha safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT langstontl safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT runyonsp safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT winstons safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT pravetonim safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse
AT pentelpr safetyandefficacyofanoxycodonevaccineaddressingsomeoftheuniqueconsiderationsposedbyopioidabuse